CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma and triple-negative breast cancer. The company's late-stage clinical drug candidates, including EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma; MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; and ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma. It also offers a portfolio of 25 U.S. food and drug administration-approved abbreviated new drug applications and 1 abbreviated new drug applications. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CASI
CUSIPN/A
Phone240-864-2600
Debt
Debt-to-Equity Ratio0.02
Current Ratio25.53
Quick Ratio25.53
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$50,000.00
Price / Sales12,903.77
Cash FlowN/A
Price / CashN/A
Book Value$0.55 per share
Price / Book13.62
Profitability
EPS (Most Recent Fiscal Year)($0.18)
Net Income$-10,770,000.00
Net MarginsN/A
Return on Equity-36.51%
Return on Assets-31.05%
Miscellaneous
Employees51
Outstanding Shares86,140,000
Market Cap$628.86
CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions
What is CASI Pharmaceuticals' stock symbol?
CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."
How were CASI Pharmaceuticals' earnings last quarter?
CASI Pharmaceuticals Inc (NASDAQ:CASI) released its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02. View CASI Pharmaceuticals' Earnings History.
When is CASI Pharmaceuticals' next earnings date?
What price target have analysts set for CASI?
2 analysts have issued twelve-month target prices for CASI Pharmaceuticals' stock. Their predictions range from $4.00 to $7.00. On average, they anticipate CASI Pharmaceuticals' stock price to reach $5.50 in the next twelve months. This suggests that the stock has a possible downside of 26.6%. View Analyst Ratings for CASI Pharmaceuticals.
What is the consensus analysts' recommendation for CASI Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about CASI Pharmaceuticals stock?
Here are some recent quotes from research analysts about CASI Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Acquisition of Sandoz Portfolio Could Lead to Commerical Launch in 12 Months; Reiterate Buy A transformative acquisition. On January 26, CASI announced the acquisition of an abbreviated new drug application (ANDA) portfolio from Sandoz, the generic drug division of Novartis (NVS; not rated), for $18M. The portfolio includes several essential medications such as Entecavir, Lisinopril, Methimazole, and Midodrine and covers a broad spectrum of drugs such as antivirals, anti-depressants, hypertension drugs, and anti-inflammatory drugs. In our view, the acquisition of these 25 approved and 4 pending ANDAs is a transformative event for the company. With the worldwide ANDA data exclusivity, CASI can now quickly become a commercial force in both China and the US." (1/29/2018)
- 2. Maxim Group analysts commented, "CASI Pharmaceuticals reported 3Q17 with a net loss of $1.6M and ended the period with $21.6M in cash. The company completed an equity financing in October, raising $23.8M. Combined, we estimate CASI currently has $44M on the balance sheet, sufficient runway into 2020. Our model has been adjusted accordingly. As we had already factored in future capital raises, the net effect is our price target of $4 remains unchanged." (11/14/2017)
Are investors shorting CASI Pharmaceuticals?
CASI Pharmaceuticals saw a increase in short interest in June. As of June 29th, there was short interest totalling 4,828,874 shares, an increase of 89.4% from the June 15th total of 2,550,121 shares. Based on an average daily volume of 1,886,514 shares, the short-interest ratio is currently 2.6 days. Currently, 13.2% of the company's stock are short sold. View CASI Pharmaceuticals' Current Options Chain.
Who are some of CASI Pharmaceuticals' key competitors?
Some companies that are related to CASI Pharmaceuticals include Halozyme Therapeutics (HALO), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Repligen (RGEN), Editas Medicine (EDIT), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO), Solid Biosciences (SLDB), Acorda Therapeutics (ACOR), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Cellectis (CLLS) and DBV Technologies (DBVT).
Who are CASI Pharmaceuticals' key executives?
CASI Pharmaceuticals' management team includes the folowing people:
- Dr. Wei-Wu He Ph.D., Exec. Chairman (Age 53)
- Dr. Ken Keyong Ren M.D., Ph.D., Chief Exec. Officer and Director (Age 59)
- Ms. Sara B. Capitelli CPA, Principal Accounting Officer and Vice-Pres of Fin. (Age 52)
- Ms. Cynthia Wong Hu J.D., Chief Operating Officer, Gen. Counsel and Sec. (Age 48)
- Dr. James E. Goldschmidt Ph.D., VP of Bus. Devel.
Has CASI Pharmaceuticals been receiving favorable news coverage?
News articles about CASI stock have trended somewhat negative on Tuesday, Accern Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. CASI Pharmaceuticals earned a media sentiment score of -0.03 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 41.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of CASI Pharmaceuticals?
Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CASI Pharmaceuticals' stock price today?
One share of CASI stock can currently be purchased for approximately $7.49.
How big of a company is CASI Pharmaceuticals?
CASI Pharmaceuticals has a market capitalization of $628.86 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-10,770,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. CASI Pharmaceuticals employs 51 workers across the globe.
How can I contact CASI Pharmaceuticals?
CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]
MarketBeat Community Rating for CASI Pharmaceuticals (NASDAQ CASI)
MarketBeat's community ratings are surveys of what our community members think about CASI Pharmaceuticals and other stocks. Vote "Outperform" if you believe CASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
